To learn about our parent company, Takeda Pharmaceutical Company Limited, please visit http://www.takeda.com/
For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.
Seramount Names Takeda as One of the 2021 100 Best Companies and Best Companies for Dads
U.S. Food and Drug Administration Accepts Takeda’s Supplemental Biologics License Application for Adult Prophylactic Use of VONVENDI® [von Willebrand factor (Recombinant)]
The Children’s National Hospital Rare Disease Institute and Takeda Partner to Standardize Care for Patients With Rare Diseases
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
TAKEDA FURTHER ENABLES HEMOPHILIA A PERSONALIZED CARE WITH LAUNCH OF MYPKFIT® SOFTWARE FOR ADYNOVATE ® [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED]
SEE ALL NEWS AND RELEASES >
Copyright 2021 Takeda Pharmaceutical Company Limited. All rights reserved.Certified Top Employer
You are about to leave www.Takeda.com/en-us and be redirected to another Takeda domain.